Form 4 for LCTX Lineage Cell Therapeutics, Inc.
Accepted 2022-03-29 00:00:00 ET · period of report 2022-03-28 · accession 0001493152-22-008029 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-29 | 2022-03-28 | LCTX | Amin Dipti | Dir | P - Purchase | $1.63 | +35.0K | 35.0K | New | +$57.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares, no par value | 2022-03-28 | P | A | 35,000 | $1.63 | 35,000 | D | — | — | (F1) The price reported is a weighted average. The shares were purchased in multiple transactions at prices ranging from not less than $1.48 to not more than $1.66. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within such range. |